[Clinical application of latamoxef during the perinatal period].
Latamoxef (LMOX), a new semisynthetic beta-lactam antibiotic developed by Shionogi Research Laboratory, was evaluated basically and clinically in the perinatal period. In basal study, concentrations of LMOX on maternal serum, umbilical card serum and amniotic fluid were measured by intravenous injection method, and that's placental transferences were relatively favorable. The ratios of umbilical cord serum to maternal serum were 1/3--1/5 at early state after administration, 5--20 minutes, 2/3 at 1.5--1.75 hours. Umbilical serum concentrations were higher than maternal serum concentrations after about 2.5 hours of administration. In 1 case, transferences into tissues of uterus and placenta were studied, that's values were 13.4 and 13.0 micrograms/g at 1.75 hours after administration, respectively. In clinical application, LMOX was administered to 4 cases (intrauterine infection 1 case, urinary tract infection 3 cases) at dose of 2.0 g twice a day by intravenous drip infusion, intravenous injection and intramuscular injection method. Excellent and good clinical response was observed in all 4 cases, and bacteriological response to causative organisms was satisfactory in 3 cases except S. faecalis of mixed infection case. No side effect or abnormal laboratory values were noticed in the all cases.
D000328:Adult; D004341:Drug Evaluation; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D009070:Moxalactam / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D009070:Moxalactam